Quantcast

PanGenex (PGXC) Enters into Negotiations With Multiple Nationwide Distributors

September 9, 2008

PanGenex Corporation (Pink Sheets:PGXC) is currently negotiating with several vendors from around the country following a successful product showcase at the Florida Chiropractic Association National Convention and Expo from August 22nd thru August 24th.

The relationships built at the event have opened the door to a new era for the company which will allow PanGenex to expand the product line effectively without spending valuable capital resources on marketing efforts.

“It is very exciting to have built relationships with well-respected distributors in the nutraceutical and pharmaceutical arenas. In addition to the new relationship with Medivisor, Inc. (Pink Sheets:MVSR – News) we will be announcing the completion of revenue share and distribution agreements before month end,” states Jeff Roman, President and CEO of PanGenex. “The vendors we are currently working with utilize some innovative new e-Commerce platforms and traditional distribution to bring products to the marketplace and most importantly, to the physician community.”

About PanGenex Corporation:

PanGenex is a publicly traded corporation (PINK SHEETS:PGXC) and pursues business opportunities in the $70 billion dollar nutraceutical and dietary supplement industry. With a focus on the cardiovascular health segment, PanGenex develops and markets sector leading, patented or patent pending, condition specific nutraceuticals and topical over-the-counter (OTC) drugs and personal care products. Each product is scientifically formulated to address specific health conditions. Many of our products contain the purest grade of nutraceutical components available anywhere without a prescription. PanGenex markets products through healthcare practitioners, retail establishments and the internet on websites such as www.PanGenex.com, www.Calgenex.com and www.HeartHealthyWorld.com .

Disclaimer:

Cautionary Statement about Forward-Looking Statements

This press release contains “forward-looking statements,” which are statements related to future, not past, events. In this context, the forward-looking statements often include statements regarding our goals, plans, projections and guidance regarding our financial position, results of operations, market position, pending and potential future acquisitions and business strategy, and often contain words such as “expects,”"anticipates,”"intends,”"plans,”"believes,”"seeks” or “will.” Any such forward-looking statements are not assurances of future performance and involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. These risks and uncertainties include, among other things, (a) general economic and business conditions, (b) the level of strategic partner incentives, (c) the future regulatory environment, (d) our cost of financing, (e) our ability to complete acquisitions and dispositions and the risks associated therewith, and (f) our ability to retain key personnel. These factors, as well as additional factors, could affect our forward-looking statements. We urge you to carefully consider this information. We undertake no duty to update our forward-looking statements, including our earnings outlook. The statements in this press release have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.




comments powered by Disqus